Standard

Meta-analysis of predictors of all-cause mortality after transcatheter aortic valve implantation. / Giordana, Francesca; D'Ascenzo, Fabrizio; Nijhoff, Freek et al.

In: American journal of cardiology, Vol. 114, No. 9, 2014, p. 1447-1455.

Research output: Contribution to journalArticleAcademicpeer-review

Harvard

Giordana, F, D'Ascenzo, F, Nijhoff, F, Moretti, C, D'Amico, M, Biondi Zoccai, G, Sinning, JM, Nickenig, G, van Mieghem, NM, Chieffo, A, Dumonteil, N, Tchetche, D, Barbash, IM, Waksman, R, D'Onofrio, A, Lefevre, T, Pilgrim, T, Amabile, N, Codner, P, Kornowski, R, Yong, ZY, Baan, J, Colombo, A, Latib, A, Salizzoni, S, Omedè, P, Conrotto, F, La Torre, M, Marra, S, Rinaldi, M & Gaita, F 2014, 'Meta-analysis of predictors of all-cause mortality after transcatheter aortic valve implantation', American journal of cardiology, vol. 114, no. 9, pp. 1447-1455. https://doi.org/10.1016/j.amjcard.2014.07.081

APA

Giordana, F., D'Ascenzo, F., Nijhoff, F., Moretti, C., D'Amico, M., Biondi Zoccai, G., Sinning, J. M., Nickenig, G., van Mieghem, N. M., Chieffo, A., Dumonteil, N., Tchetche, D., Barbash, I. M., Waksman, R., D'Onofrio, A., Lefevre, T., Pilgrim, T., Amabile, N., Codner, P., ... Gaita, F. (2014). Meta-analysis of predictors of all-cause mortality after transcatheter aortic valve implantation. American journal of cardiology, 114(9), 1447-1455. https://doi.org/10.1016/j.amjcard.2014.07.081

Vancouver

Giordana F, D'Ascenzo F, Nijhoff F, Moretti C, D'Amico M, Biondi Zoccai G et al. Meta-analysis of predictors of all-cause mortality after transcatheter aortic valve implantation. American journal of cardiology. 2014;114(9):1447-1455. doi: 10.1016/j.amjcard.2014.07.081

Author

Giordana, Francesca ; D'Ascenzo, Fabrizio ; Nijhoff, Freek et al. / Meta-analysis of predictors of all-cause mortality after transcatheter aortic valve implantation. In: American journal of cardiology. 2014 ; Vol. 114, No. 9. pp. 1447-1455.

BibTeX

@article{366f3d81fc194fdda70a860a6632f06a,
title = "Meta-analysis of predictors of all-cause mortality after transcatheter aortic valve implantation",
abstract = "The aim of this study was to identify predictors of 30-day and midterm mortality after transcatheter aortic valve implantation (TAVI) by means of a systemic review. TAVI was demonstrated to be safe and efficacious in patients with severe aortic stenosis. An accurate estimation of procedural risk of these patients represents an actual challenge. The PubMed and Cochrane Collaboration databases were systematically searched for studies reporting on the incidence and independent predictors of 30-day and midterm mortality. Adverse events were pooled with random effect, whereas independent predictors are reported as odds ratios (ORs) with 95% confidence intervals (CIs). A total of 25 studies with 8,874 patients were included (median age 82.5 ± 1.5 years, 54.6% women). At 30 days, 7.5% of patients (n = 663) died. At midterm follow-up (median 365 days, interquartile range 267 to 365 days), the cumulative mortality rate was 21.6% (n = 1,917). Acute kidney injury (AKI) stage ≥2 (OR 18.0, 95% CI 6.3 to 52), preprocedural hospitalization for heart failure (OR 9.4, 95% CI 2.6 to 35), periprocedural acute myocardial infarction (OR 8.5, 95% CI 2.6 to 33.5), and increased pro-brain natriuretic peptide (pro-BNP) levels (OR 5.4, 95% CI 1.7 to 16.5) were the most important independent predictors of 30-day mortality. Increased pro-BNP levels (OR 11, 95% CI 1.5 to 81), AKI stage 3 (OR 6.8, 95% CI 2.6 to 15.7), left ventricular ejection fraction <30% (OR 6.7, 95% CI 3.5 to 12.7), and periprocedural acute myocardial infarction (OR 6.5, 95% CI 2.3 to 18.1) represented the predictors of midterm mortality. In conclusion, in this large meta-analysis of patients undergoing TAVI, we found that high pro-BNP levels and postprocedural AKI were the strongest independent predictors of both 30-day and 1-year mortality. These findings may contribute to a better understanding of the risk assessment process of patients undergoing TAVI",
author = "Francesca Giordana and Fabrizio D'Ascenzo and Freek Nijhoff and Claudio Moretti and Maurizio D'Amico and {Biondi Zoccai}, Giuseppe and Sinning, {Jan Malte} and George Nickenig and {van Mieghem}, {Nicolas M.} and Adelaide Chieffo and Nicolas Dumonteil and Didier Tchetche and Barbash, {Israel M.} and Ron Waksman and Augusto D'Onofrio and Thierry Lefevre and Thomas Pilgrim and Nicolas Amabile and Pablo Codner and Ran Kornowski and Yong, {Ze Yie} and Jan Baan and Antonio Colombo and Azeem Latib and Stefano Salizzoni and Pierluigi Omed{\`e} and Federico Conrotto and {La Torre}, Michele and Sebastiano Marra and Mauro Rinaldi and Fiorenzo Gaita",
year = "2014",
doi = "10.1016/j.amjcard.2014.07.081",
language = "English",
volume = "114",
pages = "1447--1455",
journal = "American journal of cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "9",

}

RIS

TY - JOUR

T1 - Meta-analysis of predictors of all-cause mortality after transcatheter aortic valve implantation

AU - Giordana, Francesca

AU - D'Ascenzo, Fabrizio

AU - Nijhoff, Freek

AU - Moretti, Claudio

AU - D'Amico, Maurizio

AU - Biondi Zoccai, Giuseppe

AU - Sinning, Jan Malte

AU - Nickenig, George

AU - van Mieghem, Nicolas M.

AU - Chieffo, Adelaide

AU - Dumonteil, Nicolas

AU - Tchetche, Didier

AU - Barbash, Israel M.

AU - Waksman, Ron

AU - D'Onofrio, Augusto

AU - Lefevre, Thierry

AU - Pilgrim, Thomas

AU - Amabile, Nicolas

AU - Codner, Pablo

AU - Kornowski, Ran

AU - Yong, Ze Yie

AU - Baan, Jan

AU - Colombo, Antonio

AU - Latib, Azeem

AU - Salizzoni, Stefano

AU - Omedè, Pierluigi

AU - Conrotto, Federico

AU - La Torre, Michele

AU - Marra, Sebastiano

AU - Rinaldi, Mauro

AU - Gaita, Fiorenzo

PY - 2014

Y1 - 2014

N2 - The aim of this study was to identify predictors of 30-day and midterm mortality after transcatheter aortic valve implantation (TAVI) by means of a systemic review. TAVI was demonstrated to be safe and efficacious in patients with severe aortic stenosis. An accurate estimation of procedural risk of these patients represents an actual challenge. The PubMed and Cochrane Collaboration databases were systematically searched for studies reporting on the incidence and independent predictors of 30-day and midterm mortality. Adverse events were pooled with random effect, whereas independent predictors are reported as odds ratios (ORs) with 95% confidence intervals (CIs). A total of 25 studies with 8,874 patients were included (median age 82.5 ± 1.5 years, 54.6% women). At 30 days, 7.5% of patients (n = 663) died. At midterm follow-up (median 365 days, interquartile range 267 to 365 days), the cumulative mortality rate was 21.6% (n = 1,917). Acute kidney injury (AKI) stage ≥2 (OR 18.0, 95% CI 6.3 to 52), preprocedural hospitalization for heart failure (OR 9.4, 95% CI 2.6 to 35), periprocedural acute myocardial infarction (OR 8.5, 95% CI 2.6 to 33.5), and increased pro-brain natriuretic peptide (pro-BNP) levels (OR 5.4, 95% CI 1.7 to 16.5) were the most important independent predictors of 30-day mortality. Increased pro-BNP levels (OR 11, 95% CI 1.5 to 81), AKI stage 3 (OR 6.8, 95% CI 2.6 to 15.7), left ventricular ejection fraction <30% (OR 6.7, 95% CI 3.5 to 12.7), and periprocedural acute myocardial infarction (OR 6.5, 95% CI 2.3 to 18.1) represented the predictors of midterm mortality. In conclusion, in this large meta-analysis of patients undergoing TAVI, we found that high pro-BNP levels and postprocedural AKI were the strongest independent predictors of both 30-day and 1-year mortality. These findings may contribute to a better understanding of the risk assessment process of patients undergoing TAVI

AB - The aim of this study was to identify predictors of 30-day and midterm mortality after transcatheter aortic valve implantation (TAVI) by means of a systemic review. TAVI was demonstrated to be safe and efficacious in patients with severe aortic stenosis. An accurate estimation of procedural risk of these patients represents an actual challenge. The PubMed and Cochrane Collaboration databases were systematically searched for studies reporting on the incidence and independent predictors of 30-day and midterm mortality. Adverse events were pooled with random effect, whereas independent predictors are reported as odds ratios (ORs) with 95% confidence intervals (CIs). A total of 25 studies with 8,874 patients were included (median age 82.5 ± 1.5 years, 54.6% women). At 30 days, 7.5% of patients (n = 663) died. At midterm follow-up (median 365 days, interquartile range 267 to 365 days), the cumulative mortality rate was 21.6% (n = 1,917). Acute kidney injury (AKI) stage ≥2 (OR 18.0, 95% CI 6.3 to 52), preprocedural hospitalization for heart failure (OR 9.4, 95% CI 2.6 to 35), periprocedural acute myocardial infarction (OR 8.5, 95% CI 2.6 to 33.5), and increased pro-brain natriuretic peptide (pro-BNP) levels (OR 5.4, 95% CI 1.7 to 16.5) were the most important independent predictors of 30-day mortality. Increased pro-BNP levels (OR 11, 95% CI 1.5 to 81), AKI stage 3 (OR 6.8, 95% CI 2.6 to 15.7), left ventricular ejection fraction <30% (OR 6.7, 95% CI 3.5 to 12.7), and periprocedural acute myocardial infarction (OR 6.5, 95% CI 2.3 to 18.1) represented the predictors of midterm mortality. In conclusion, in this large meta-analysis of patients undergoing TAVI, we found that high pro-BNP levels and postprocedural AKI were the strongest independent predictors of both 30-day and 1-year mortality. These findings may contribute to a better understanding of the risk assessment process of patients undergoing TAVI

U2 - 10.1016/j.amjcard.2014.07.081

DO - 10.1016/j.amjcard.2014.07.081

M3 - Article

C2 - 25217456

VL - 114

SP - 1447

EP - 1455

JO - American journal of cardiology

JF - American journal of cardiology

SN - 0002-9149

IS - 9

ER -

ID: 2471457